Future Science Group has announced the launch of a new journal named Pharmaceutical Patent Analyst, which will discuss important patent issues pertaining to pharmaceutical and medical science.
The bi-monthly peer-reviewed publication will focus on high-impact patent reviews pertaining to significant areas of research, including new therapies, drug-delivery systems and medical devices, as well as bio- and nanotechnology innovations.
It will be supported by a multidisciplinary editorial board that includes academy and industry-based researchers and opinion leaders, as well as specialists in intellectual property (IP).
Heading the editorial board will be Professor David Rotella of Montclair State University and Dr Lyn Jones of Pfizer.
Elisa Manzotti, publisher at Future Science Group, said: "We are extremely grateful to the senior editors and editorial board for bringing their specialist expertise to bear to create a substantial publication that genuinely addresses core IP issues in biomedicine and biotechnology."
This comes after the company introduced Colorectal Cancer, an oncology-focused medical journal, in February 2012.